Immunotherapy for triple-negative breast cancer — who qualifies, and when

Most breast cancer patients are not candidates, and triple-negative disease is the exception rather than the rule. Within it, qualifying still depends on stage. Early triple-negative cancer above a certain size, or with involved lymph nodes, may qualify. In advanced disease, a PD-L1 combined positive score has to reach the guideline threshold first.

It is worth being blunt about the arithmetic before anything else, because the word “triple-negative” carries a lot of fear and a lot of searching. Triple-negative disease accounts for roughly one in eight to one in six breast cancers. It is the smallest of the three main subtypes and it is the one where immunotherapy has a defined place in NCCN, ASCO and ESMO guidance. That is the whole reason this page exists as its own page.

But “the subtype where it matters” is not the same as “everyone with this subtype”. A woman with a small, node-negative triple-negative tumour removed at surgery is usually not in the group guidelines describe. Neither is a woman with advanced disease whose PD-L1 score comes back below the cut-off. Both of those women are still being treated properly. They are simply being treated with the tools that fit.

Triple-negative means the pathologist found no oestrogen receptor, no progesterone receptor and no HER2 amplification on your tissue. It is not a grade and it is not a stage. It describes what the cancer is missing, not how far it has spread. Because those three targets are absent, hormone therapy and HER2-directed treatment have nothing to attach to — which is exactly why other approaches, including immune checkpoint inhibitors, were studied hardest in this subtype.

Immunotherapy on this page means immune checkpoint inhibitors as a drug class. This page names no medicine and no brand, and it recommends no treatment. At CION, immunotherapy is given as day care at our centres when it is genuinely indicated, every plan is set by a tumour board rather than by one doctor, and any cost discussed with you is indicative, as of August 2026, and confirmed in writing before treatment starts.

Both, under different rules. In early triple-negative disease it is considered where the tumour is larger or the nodes are involved, given with chemotherapy before surgery and completed afterwards, with no PD-L1 test required. In advanced disease it is added to first-line chemotherapy only when the PD-L1 score qualifies.

This table describes the shape of guideline practice, not your own plan. Exact tumour-size and node thresholds, and the PD-L1 cut-off itself, are set in NCCN, ASCO and ESMO guidance and are revised periodically; the version current when you are treated is the one that applies. Nothing here is an outcome figure of any kind. Take the line you think you are on to your oncologist and ask them to confirm it.

If you are still working out which breast cancer subtype you have, start with our wider guide to immunotherapy for breast cancer, which sets out all the subtypes side by side. This page assumes your report already says triple-negative.

In advanced disease, almost everything. A PD-L1 combined positive score at or above the guideline cut-off meets the criterion for adding a checkpoint inhibitor to chemotherapy. Below it, the criterion is not met. In early disease, before surgery, the score usually changes nothing, because guidelines do not require it there.

PD-L1 is a protein. The test looks at your existing tissue block under a microscope after staining, so no fresh procedure is needed in most cases, and results usually come back within a few working days. In breast cancer it is reported as a combined positive score, or CPS, which counts staining on tumour cells and on the immune cells around them together. That is a different scoring system from the one used in lung cancer, and the numbers are not interchangeable.

A CPS measures how much PD-L1 protein is present. It is not a prediction of what will happen to you, and no test available today can tell an individual in advance whether she will benefit. Scores can also differ between laboratories and between samples from the same person. Our explainer on what a PD-L1 score means covers the principle in more depth — read it for the idea, and take the actual numbers and cut-offs from a breast specialist, because the scoring system differs. Any cost quoted for biomarker testing is indicative, as of August 2026, and given in writing before the test is sent.

Five steps, in this order. The biopsy report confirms the subtype. Scans and pathology set the stage. If the disease is advanced, PD-L1 is sent on the same tissue block. Reasons not to give it are screened for. The tumour board then confirms the plan in writing.

1. 1

   Confirm the subtype on the report

   Oestrogen receptor, progesterone receptor and HER2 all negative. If the cancer has recurred, ask whether the receptors were re-tested on the new sample. Receptor status occasionally changes between the original tumour and a recurrence, and assuming the old result can send the whole plan the wrong way.

2. 2

   Establish the stage, the tumour size and the nodes

   This is the step that decides which set of rules applies to you. Early disease with a larger tumour or involved nodes follows one pathway; small node-negative disease follows another; advanced or recurrent disease follows a third. Scans, and the pathology report after surgery, settle it.

3. 3

   Send PD-L1 if the disease is advanced

   Run on the existing tissue block and reported as a combined positive score. In the early setting before surgery, guidelines do not require it, so it is often not sent — that is a deliberate decision, not a gap in your work-up.

4. 4

   Screen for reasons not to give it

   Active autoimmune disease, a significant steroid dose being taken for another illness, an organ transplant, poor organ function or being very unwell can all make checkpoint immunotherapy unsafe or unsuitable. This conversation happens before consent, not after.

5. 5

   Tumour board confirms, then treatment starts

   Medical, surgical and radiation oncologists review the file together and the plan is given to you in writing, including what it costs — indicative, as of August 2026. Infusions are given as day care at CION centres. Response-assessment PET-CT is coordinated at our partner imaging centres rather than done in-house.

The question of whether immunotherapy goes with chemotherapy or is ever given on its own comes up constantly, and it is answered differently in different cancers. Our page on immunotherapy alone or with chemotherapy works through that decision in lung cancer, where both routes genuinely exist. In triple-negative breast cancer the guideline answer is simpler: it is added to chemotherapy, not given instead of it.

Four groups, mainly. Small node-negative early tumours that do not meet the size and node criteria. Advanced disease with a PD-L1 score below the cut-off. Patients with active autoimmune disease, on significant steroids, or with a transplant. And patients too unwell to tolerate it safely.

Being told no after reading that your subtype is “the one where immunotherapy works” is a particular kind of disappointment, and it deserves a straight explanation rather than a soft one. Each of those four reasons is a different kind of no. The first two are about criteria: the evidence supporting the treatment was built in specific populations, and guidelines recommend it for the population it was tested in. The second two are about safety: releasing an immune brake in someone whose immune system is already attacking their own tissue, or who is on steroids that blunt the effect, carries real risk without a matching expectation of benefit.

What does not change is that you are being offered full treatment. Surgery, chemotherapy and radiation therapy are the established backbone of triple-negative care and they do the heavy lifting for most patients regardless of immunotherapy. In advanced disease, other drug classes — including antibody-drug conjugates, and targeted options where an inherited or tumour mutation fits — are part of the picture too. Testing for an inherited BRCA change is worth asking about in triple-negative disease, because it can open a different targeted option and it matters for your family.

It is also worth knowing that this arithmetic is not unique to breast cancer. Immunotherapy is used far more widely in lung cancer, and even there a large group of patients does not qualify — our page on who benefits from immunotherapy in lung cancer sets out the same kind of eligibility test for that disease. Across every cancer, immunotherapy is a defined tool for defined situations.

• Ask which of the four reasons applies to you, in one sentence, and ask for it written on your consultation summary.
• Ask whether the receptor tests were repeated if the cancer has come back.
• Ask whether a PD-L1 test is needed at all for your stage before paying for one privately.
• Ask whether BRCA or wider genetic testing is appropriate, and what it would change.
• Ask what the full plan costs — indicative, as of August 2026 — and whether Aarogyasri, CGHS, ECHS, ESI or your insurance covers part of it.

CION is a woman-headed organisation and breast cancer is the disease our teams see most. Every consultation is 45 minutes, every plan goes to a tumour board, and no test is ordered that will not change a decision. If you have been advised immunotherapy elsewhere and cannot see which line of the table above you are on, that is exactly the question a second opinion is for.

Most of the confusion about immunotherapy in triple-negative breast cancer comes from mixing up the early and the advanced rules. These five questions get you a complete answer in a single appointment, whichever way it goes.

• Is my disease early or advanced, and which set of eligibility rules does that put me in?
• Does my plan need a PD-L1 result, and if so, has it been sent and what did it say?
• If immunotherapy is in my plan, what is it being added to, and for how many cycles?
• If it is not in my plan, which of the reasons applies, and what is doing the work instead?
• What is the estimated cost of the full plan, and what will insurance or a government scheme cover?

Related reading

• PD-L1 Testing in Lung Cancer: What Your Score Means — the clearest explanation of how PD-L1 scoring works, useful for the principle even though breast cancer uses a different scoring system.
• Immunotherapy Alone or With Chemotherapy for Lung Cancer? — why that choice genuinely exists in lung cancer, and why in triple-negative breast cancer the answer is simply “with”.
• Immunotherapy for Lung Cancer: Who Benefits and How Much — how eligibility is decided in the cancer where immunotherapy is used most, and why a large group still does not qualify.
• Immunotherapy at CION Cancer Clinics — how immunotherapy is delivered as day care, how response scans are coordinated with our partner imaging centres, and how costs are set out in writing.

If you would rather not work through this alone, bring your biopsy report and your scan reports to a consultation. Forty-five minutes with a medical oncologist, and a tumour board review afterwards, will tell you which line of the table you are on and what follows from it.

This page is general information and does not replace a consultation. It describes treatment classes only, not specific medicines or brands, and it recommends no treatment. Eligibility criteria, subtype proportions and biomarker thresholds are drawn from NCCN, ASCO and ESMO patient-education guidance current in August 2026 and can change; no outcome or survival figure of any kind is stated or implied. Every decision about your treatment belongs with your own treating team.

Get a second opinion on your triple-negative plan

Free, written, and reviewed by our tumour board — so you know why each treatment is in your plan and why the others are not.